Clinical trial
STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma
NCT00084214 · Synta Pharmaceuticals Corp., Industry · Completed
Key facts
| NCT number | NCT00084214 |
|---|---|
| Title | STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma |
| Official title | A Two-Stage Trial of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Metastatic Melanoma |
| Lead sponsor | Synta Pharmaceuticals Corp., Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Drug |
| Interventions | STA-4783, Paclitaxel |
| Enrollment | 103 |
| Start date | May 1, 2004 |
| First posted | Jun 10, 2004 |
| Last update posted | Mar 6, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: